Literature DB >> 22836614

Expression of Ki-67, Bcl-2, Survivin and p53 Proteins in Patients with Pulmonary Carcinoma.

E Halasova1, M Adamkov, T Matakova, D Vybohova, M Antosova, M Janickova, A Singliar, D Dobrota, V Jakusova.   

Abstract

Apoptosis is the fundamental process necessary for eliminating damaged or mutated cells. Alterations in the apoptotic pathway appear to be key events in cancer development and progression. Bcl-2 is the key member of the Bcl-2 family of apoptosis regulator proteins with anti-apoptotic effects. Survivin acts as an inhibitor of apoptosis as well and has been implicated in both inhibition of apoptosis and mitosis regulation. p53 is one of the tumor suppressor proteins, prevents tumor formation through cell cycle blocking and eliminates damaged cells via the activation of apoptosis. The Ki-67 protein is a cellular marker for proliferation. To investigate the possible interactions of the aforementioned proteins, we examined their expression in 76 patients with diagnosed lung cancer using immunohistochemical visualisation. Ki-67 protein was expressed in the cancer cells of all patients with small cell lung cancer (SCLC). We found a negative correlation between survivin and p53 expression. A decreased intensity of survivin expression and fewer cells positive for survivin (66.7%) in SCLC in comparison with other lung cancer types (98.0%) was detected. Reversely, expression of Bcl-2 was found in more than 90% of cases with SCLC. We hypothesize that high expression and intensity of Bcl-2 protein could be a factor behind a bad prognosis in SCLC.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 22836614     DOI: 10.1007/978-94-007-4549-0_3

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  5 in total

1.  Survivin expression modulates the sensitivity of A549 lung cancer cells resistance to vincristine.

Authors:  Chengwei Zhou; Yonggang Zhu; Bin Lu; Weijun Zhao; Xiaodong Zhao
Journal:  Oncol Lett       Date:  2018-08-07       Impact factor: 2.967

2.  Anticancer activity of 2'-hydroxyflavanone towards lung cancer.

Authors:  Sanjay Awasthi; Sharad S Singhal; Jyotsana Singhal; Lokesh Nagaprashantha; Hongzhi Li; Yate-Ching Yuan; Zheng Liu; David Berz; Henry Igid; William C Green; Lukman Tijani; Vijay Tonk; Aditya Rajan; Yogesh Awasthi; Sharda P Singh
Journal:  Oncotarget       Date:  2018-11-16

Review 3.  The intrinsically disorderly story of Ki-67.

Authors:  Lucy Remnant; Natalia Y Kochanova; Caitlin Reid; Fernanda Cisneros-Soberanis; William C Earnshaw
Journal:  Open Biol       Date:  2021-08-11       Impact factor: 6.411

4.  Synergy of Taxol and rhein lysinate associated with the downregulation of ERK activation in lung carcinoma cells.

Authors:  Yong-Zhan Zhen; Gang Hu; Yu-Fang Zhao; Feng Yan; Ran Li; Jun-Ling Gao; Ya-Jun Lin
Journal:  Oncol Lett       Date:  2013-06-14       Impact factor: 2.967

5.  Survivin protein expression is involved in the progression of non-small cell lung cancer in Asians: a meta-analysis.

Authors:  Liang Duan; Xuefei Hu; Yuxing Jin; Ruijun Liu; Qingjun You
Journal:  BMC Cancer       Date:  2016-04-18       Impact factor: 4.430

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.